ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 595,11
-0,49%
Dow Jones
40 211,72
0,53%
DAX
18 526,37
-0,40%
Brent Oil
83,575
-0,91%
Bitcoin
62 961,03
-2,92%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
31/12/202117h06TipRanksTeva Found Guilty of Fueling New York Opioid CrisisNYSE:TEVATeva Pharmaceutical Industries Ltd
30/12/202119h29Business WireTeva Statement Following New York Jury Ruling in Opioids TrialNYSE:TEVATeva Pharmaceutical Industries Ltd
30/12/202119h05Dow Jones NewsTeva Fueled Opioid Addiction in New York, Jury Finds -- ReutersNYSE:TEVATeva Pharmaceutical Industries Ltd
29/12/202109h27TipRanksTeva Long-Term Prospects Bright, Despite HeadwindsNYSE:TEVATeva Pharmaceutical Industries Ltd
27/12/202110h11TipRanksTeva Partners with Tikun Olam-Cannbit to Sell Medical Cannabis Products – ReportNYSE:TEVATeva Pharmaceutical Industries Ltd
23/12/202114h54TipRanksTeva Launches First Generic of Naloxone Hydrochloride Nasal Spray in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
22/12/202122h30Business WireTeva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/202115h43Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/12/202114h00Business WireTeva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
25/11/202118h00GlobeNewswire Inc.Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.NYSE:TEVATeva Pharmaceutical Industries Ltd
24/11/202113h51Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
10/11/202115h17Business WireTeva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/11/202111h56Business WireVon der Effektivität im Rahmen klinischer Versuchsreihen zur tatsächlichen Wirksamkeit - erste Daten zu AJOVY® ▼ (Fremanezumab) aus dem European Real World Evidence ProgrammNYSE:TEVATeva Pharmaceutical Industries Ltd
09/11/202111h54Business WireDe l'efficacité clinique à l'efficacité en monde réel : les premières données AJOVY® ▼ ▼ (frémanezumab) du programme European Real World EvidenceNYSE:TEVATeva Pharmaceutical Industries Ltd
08/11/202122h02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
08/11/202110h25Business WireFrom Clinical Trial Efficacy to Real-World Effectiveness First AJOVY® ▼ (fremanezumab) Data from European Real World Evidence ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
04/11/202121h43Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/11/202111h00Business WireTeva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine TargetsNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202122h31Business WireTeva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202122h30Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202103h00Business WireCalifornia Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About OpioidsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/10/202122h00Business WireNew Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202114h52Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h15Business WireTeva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024NYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h15Business WireTeva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h14Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h00Business WireTeva Reports Third Quarter 2021 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
26/10/202122h45Business WireTeva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug CandidateNYSE:TEVATeva Pharmaceutical Industries Ltd
21/10/202114h00Business WireTeva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021NYSE:TEVATeva Pharmaceutical Industries Ltd
13/10/202119h53Business WireNouvelles données relatives à l'innocuité du traitement par COPAXONE® (acétate de glatiramère) chez des mères allaitantes atteintes de sclérose en plaques cycliqueNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

NASDAQ
SNAK
Poore Brothers
KOSDAQ
076610
Haesung Optics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés